Compare Novartis AG (NVS) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Raytheon Technologies Corp — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Raytheon Technologies Corp trades at $185.97 (market cap $248.42B). The key difference: Novartis AG and Raytheon Technologies Corp are close in size by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Raytheon Technologies Corp for 77 Days on average.
| NVS | RTX | |
|---|---|---|
Market Cap | $268.57B | $248.42B |
Volume | 1,532,573 | 4,380,368 |
Sector | Health | Industrials |
52-Week High | $168.62 | $225.49 |
52-Week Low | $121.80 | $157.00 |
Typical Hold Time | 82 Days | 77 Days |
Enterprise Value | $309.89B | $278.97B |
Dividend Yield | 3.31% | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
RTX trades at $184.32, up 2.25% with strong earnings momentum as Q1 and Q2 2026 results beat expectations. The stock shows bearish technical signals but benefits from a $289 billion backlog and rising defense spending. Revenue grew to $88.6 billion in 2025 with net income of $6.73 billion, while analyst consensus remains bullish with a $236.27 price target.
Outlook is positive given defense budget tailwinds and operational execution, though technical weakness and debt levels pose risks. The company's dividend and backlog provide stability, but investors should monitor geopolitical impacts and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
